Opalesque Industry Update - Over the past 12 years, the Vulpes partners have acquired significant stakes in a small
number of selective, largely UK-based, life-science companies which they believe offer a
huge discount to fair value.|
These assets will now be offered in a fund structure for co-investment, continuing our plan to move all the partners’ significant assets into fund structures available for external investors.
Summary of Vulpes Life Sciences Fund:
• Small number of companies where IP/technology around diagnostics or drug
discovery is very large compared to valuations
“The UK venture capital market in life sciences in the UK can be very undervalued compared to the world class ideas coming out of UK universities and research institutes which has left the sector somewhat orphaned. We see great potential value in lifescience companies housing world-leading research and development and making significant advances in the treatment of a number of major diseases” said Stephen Diggle, Founder. “The Vulpes Life-Sciences Fund will focus on a select group of companies that possess significantly undervalued intellectual property in both diagnostics and discovery, and will use Vulpes’ experience and expertise to help maximize their commercial value”.
Vulpes Investment Management launched on 1st April 2011 and now has 5 funds open to investors: Long Asian Volatility and Arbitrage Fund, Russian Opportunities Fund and Testudo Fund; the Creo European Investments Fund and now the Vulpes Life Sciences Fund. The Vulpes Agricultural Fund will be added to the platform in the coming months. Corporate website:Source